Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its target price dropped by investment analysts at Needham & Company LLC from $46.00 to $44.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC‘s target price points to a potential upside of 81.74% from the company’s previous close.
Several other research firms have also recently weighed in on COLL. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Zacks Research upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Finally, Leerink Partners started coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $44.88.
Get Our Latest Report on Collegium Pharmaceutical
Collegium Pharmaceutical Price Performance
Shares of COLL stock traded down $0.95 during trading hours on Thursday, reaching $24.21. The stock had a trading volume of 775,375 shares, compared to its average volume of 622,329. The stock’s fifty day simple moving average is $22.99 and its 200 day simple moving average is $32.79. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 12 month low of $21.43 and a 12 month high of $50.79. The firm has a market capitalization of $788.28 million, a PE ratio of 24.21, a PEG ratio of 0.74 and a beta of 0.75.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.10. The business had revenue of $216.34 million for the quarter, compared to analyst estimates of $216.03 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. Collegium Pharmaceutical’s revenue was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.25 EPS. On average, equities research analysts predict that Collegium Pharmaceutical will post 6.42 EPS for the current year.
Institutional Investors Weigh In On Collegium Pharmaceutical
A number of hedge funds have recently made changes to their positions in COLL. Ritholtz Wealth Management raised its position in Collegium Pharmaceutical by 150.7% in the 3rd quarter. Ritholtz Wealth Management now owns 20,305 shares of the specialty pharmaceutical company’s stock worth $443,000 after purchasing an additional 12,205 shares during the period. Illinois Municipal Retirement Fund boosted its position in Collegium Pharmaceutical by 10.0% during the third quarter. Illinois Municipal Retirement Fund now owns 17,696 shares of the specialty pharmaceutical company’s stock valued at $386,000 after buying an additional 1,607 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Collegium Pharmaceutical during the third quarter valued at about $36,000. Profund Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 621.1% during the third quarter. Profund Advisors LLC now owns 65,710 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after buying an additional 56,597 shares during the last quarter. Finally, Vise Technologies Inc. increased its stake in Collegium Pharmaceutical by 154.3% in the 3rd quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 9,006 shares during the period.
Collegium Pharmaceutical News Roundup
Here are the key news stories impacting Collegium Pharmaceutical this week:
- Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
- Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
- Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
- Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
- Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.
Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.
Recommended Stories
- Five stocks we like better than Collegium Pharmaceutical
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
